|
Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will join other vaccine industry leaders for a panel discussion at the 2019 BIO International Convention. Taking place in Philadelphia, Pennsylvania on Wednesday, June 5 at 11:00 a.m. EDT, the panel will cover the future of influenza vaccines, including regulatory process opportunities and challenges, real-world evidence, and investment costs and data that informs market uptake to help fulfill global health community goals for influenza prevention. Details for the panel are as follows:
About Novavax Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs. For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn. Contacts: Westwicke Partners
 |
|
